ATOSSA THERAPEUTICS, INC. (ATOS) [Rocket]

Overview

ATOSSA THERAPEUTICS, INC. (ATOS)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/06/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/28/2023	8-K	Quarterly results
08/14/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/14/2023	8-K	Quarterly results
07/13/2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/01/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/15/2023	10-Q	Quarterly Report for the period ended March 31, 2023

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Revenue growth							-100.0%	-95.6%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1
Gross margin								-7431.9%
Sales and marketing								1.4
Research and development	15.1	9.2	6.6	6.6	4.2	2.3	0.8	2.4
General and administrative	12.6	11.3	8.0	10.6	7.2	4.9	6.5	8.8
EBITA	-27.7	-20.5	-14.6	-17.2	-11.4	-7.1	-7.2	-12.8
EBITA margin								-725746.2%
Amortization of intangibles				0.0	0.0	0.1
EBIT	-27.7	-20.5	-14.6	-17.3	-11.4	-7.2	-7.2	-12.8
EBIT margin								-725746.2%
Pre-tax income	-27.0	-20.6	-17.8	-17.2	-11.4	-8.1	-6.4	-12.8
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-27.0	-20.6	-22.3	-17.2	-22.9	-10.7	-6.4	-15.8
Net margin								-896491.6%

Diluted EPS	($0.21)	($0.18)	($1.97)	($2.03)	($5.50)	($10.97)	($2.16)	($6.73)
Shares outstanding (diluted)	126.6	117.0	11.3	8.5	4.2	1.0	2.9	1.9

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.